Last reviewed · How we verify

Medigen Vaccine Biologics Corp. — Portfolio Competitive Intelligence Brief

Medigen Vaccine Biologics Corp. pipeline: 0 marketed, 0 filed, 4 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 4 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
EV71vac EV71vac phase 3 Inactivated viral vaccine Enterovirus 71 (EV71) Immunology / Infectious Disease
GC FLU Quadrivalent GC FLU Quadrivalent phase 3 Inactivated influenza vaccine Immunology / Infectious Disease
Envacgen® Envacgen® phase 3 Recombinant protein subunit vaccine Immunology / Infectious Disease
MVC-COV1901 MVC-COV1901 phase 3 Protein subunit vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Novavax · 2 shared drug classes
  2. Sinovac Biotech Co., Ltd · 2 shared drug classes
  3. Green Cross Corporation · 2 shared drug classes
  4. Novartis · 2 shared drug classes
  5. Pfizer · 2 shared drug classes
  6. Sanofi Pasteur, a Sanofi Company · 2 shared drug classes
  7. GlaxoSmithKline · 2 shared drug classes
  8. Brigham and Women's Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Medigen Vaccine Biologics Corp.:

Cite this brief

Drug Landscape (2026). Medigen Vaccine Biologics Corp. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medigen-vaccine-biologics-corp. Accessed 2026-05-18.

Related